NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.
Ticker SymbolNURO
Company nameNeuroMetrix Inc
IPO dateJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
Number of employees13
Security typeOrdinary Share
Fiscal year-endJul 22
Address1000 Winter Street
CityWALTHAM
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code02451
Phone17818909989
Websitehttps://www.neurometrix.com/
Ticker SymbolNURO
IPO dateJul 22, 2004
CEODr. Shai N. Gozani, M.D., Ph.D.
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data